Expertise in
14
conditions

Dr. Gurkamal S. Chatta

Oncology | Hematology Oncology
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
Offers Telehealth
Expertise in
14
conditions
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gurkamal Chatta is an Oncologist and a Hematologist Oncology provider in Buffalo, New York. Dr. Chatta is highly rated in 14 conditions, according to our data. His top areas of expertise are Prostate Cancer, Bladder Cancer, Urothelial Cancer, Prostatectomy, and Orchiectomy.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Specialist in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

ROSWELL PARK CANCER INSTITUTE
Elm And Carlton St, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen
Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2025
Intervention Type: Biological, Procedure, Drug
Study Drugs: Aspirin, Recombinant Interferon Alfa-2b, Rintatolimod
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Biological
Study Drugs: Enoblituzumab, Pembrolizumab, MGA012 Anti-PD-1 Antibody
Study Phase: Phase 1
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
A Phase 1b Clinical Trial: Improving Outcomes With Androgen Pathway Inhibitors by Targeting DNA Methyltransferase Activity
A Phase 1b Clinical Trial: Improving Outcomes With Androgen Pathway Inhibitors by Targeting DNA Methyltransferase Activity
Enrollment Status: Terminated
Publish Date: February 28, 2025
Intervention Type: Drug
Study Drugs: Decitabine and Cedazuridine, Enzalutamide
Study Phase: Phase 1
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Procedure, Other, Biological, Drug
Study Drugs: Atezolizumab, Glycosylated Recombinant IL-7
Study Phase: Phase 2
Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drugs: Enzalutamide, Venetoclax
Study Phase: Phase 1
Phase Ib/II Study of Enzalutamide With Decitabine, a DNA Hypomethylating Agent, in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase Ib/II Study of Enzalutamide With Decitabine, a DNA Hypomethylating Agent, in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment Status: Withdrawn
Publish Date: October 05, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Genetic
Study Phase: Phase 1
View 8 Less Clinical Trials

46 Total Publications

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes.
Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes.
Journal: bioRxiv : the preprint server for biology
Published: July 17, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Eunice S. Wang
Hematology Oncology | Hematology | Oncology
Expertise in
25
conditions
Dr. Eunice S. Wang
Hematology Oncology | Hematology | Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Eunice Wang is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Wang is highly rated in 25 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Expertise in
15
conditions
Dr. Grace K. Dy
Hematology Oncology | Hematology | Oncology
Expertise in
15
conditions
Dr. Grace K. Dy
Hematology Oncology | Hematology | Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Grace Dy is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Dy is highly rated in 15 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Lymphadenectomy.

Expertise in
28
conditions
Dr. Elizabeth A. Griffiths
Hematology Oncology | Hematology | Oncology
Expertise in
28
conditions
Dr. Elizabeth A. Griffiths
Hematology Oncology | Hematology | Oncology
Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Elizabeth Griffiths is a Hematologist Oncology specialist and a Hematologist in Buffalo, New York. Dr. Griffiths is highly rated in 28 conditions, according to our data. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelomonocytic Leukemia (CMML), and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chatta's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile